Circulating Adipocytokines and Insulin Like-Growth Factors and Their Modulation in Obesity-Associated Endometrial Cancer.

adipocytokines body mass index endometrial cancer risk insulin-like growth factor obesity

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
26 Jan 2024
Historique:
received: 30 11 2023
revised: 13 01 2024
accepted: 23 01 2024
medline: 10 2 2024
pubmed: 10 2 2024
entrez: 10 2 2024
Statut: epublish

Résumé

The rising global incidence of uterine cancer is linked to the escalating prevalence of obesity. Obesity results in alterations in adipocytokines and IGFs, driving cancer progression via inflammation, increased cell proliferation, and apoptosis inhibition, although the precise mechanisms are still unclear. This study examined a set of six markers, namely, adiponectin, leptin, IL6, TNFα, IGF1, and IGF2 and compared them between fifty age-matched endometrial cancer patients (study group) and non-cancer patients with benign gynaecological conditions (control group). We also assessed the relationship of these markers with obesity and explored the correlation between these markers and various tumour characteristics. In the cancer population, these markers were also assessed 24 h and 6 months post-surgery. Remarkably, low adiponectin levels were associated with a 35.8% increase in endometrial cancer risk. Interestingly, compared to control subjects where IGF levels decreased after menopause, post-menopausal women in the study group showed elevated IGF1 and IGF2 levels, suggesting a potential influence of endometrial cancer on the IGF system, particularly after menopause. Lastly, it is noteworthy that a discernible inverse relationship trend was observed in the levels of adipocytokines and IGFs 6 months post-surgery. This indicates that treatment for endometrial cancer may have a differential impact on adipocytokines and IGFs, potentially holding clinical significance that merits further investigation.

Identifiants

pubmed: 38339282
pii: cancers16030531
doi: 10.3390/cancers16030531
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : GRACE charity
ID : Irene Ray

Auteurs

Irene Ray (I)

Department of Clinical and Experimental Medicine, University of Surrey, Daphne Jackson Road, Guildford GU2 7WG, UK.
Academic Department of Gynaecological Oncology, Royal Surrey NHS Foundation Trust, Egerton Road, Guildford GU2 7XX, UK.

Carla S Möller-Levet (CS)

Bioinformatics Core Facility, University of Surrey, Daphne Jackson Road, Guildford GU2 7WG, UK.

Agnieszka Michael (A)

Department of Clinical and Experimental Medicine, University of Surrey, Daphne Jackson Road, Guildford GU2 7WG, UK.
Department of Oncology, Royal Surrey NHS Foundation Trust, Egerton Road, Guildford GU2 7XX, UK.

Simon Butler-Manuel (S)

Academic Department of Gynaecological Oncology, Royal Surrey NHS Foundation Trust, Egerton Road, Guildford GU2 7XX, UK.

Jayanta Chatterjee (J)

Academic Department of Gynaecological Oncology, Royal Surrey NHS Foundation Trust, Egerton Road, Guildford GU2 7XX, UK.
Department of Life Sciences, Brunel University London, Kingston Lane Uxbridge, Middlesex, Uxbridge UB8 3PH, UK.

Anil Tailor (A)

Academic Department of Gynaecological Oncology, Royal Surrey NHS Foundation Trust, Egerton Road, Guildford GU2 7XX, UK.

Patricia E Ellis (PE)

Department of Clinical and Experimental Medicine, University of Surrey, Daphne Jackson Road, Guildford GU2 7WG, UK.
Academic Department of Gynaecological Oncology, Royal Surrey NHS Foundation Trust, Egerton Road, Guildford GU2 7XX, UK.

Lisiane B Meira (LB)

Department of Clinical and Experimental Medicine, University of Surrey, Daphne Jackson Road, Guildford GU2 7WG, UK.

Classifications MeSH